CLINUVEL PHARMACEUTICALS LTD

Home
Australia
Melbourne, VIC
CLINUVEL PHARMACEUTICALS LTD

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CLINUVEL PHARMACEUTICALS LTD, Medical and health, 535 Bourke Street, Melbourne.

CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations.

19/01/2026

We had the privilege of hosting Reuben Sam and several other speakers at our Pavilion of Photomedicine at .

During an intimate session, Reuben shared his lived experience with vitiligo and advocated strongly for mental health support to be provided in alongside dermatologic care.

We are looking forward to continuing the important conversation on psychodermatology at .

More details to come!

15/01/2026

CLINUVEL enters 2026 focused on high-impact milestones. Managing Director, Dr Philippe Wolgen’s latest letter outlines a path to a A$7.5B valuation, driven by organic growth and financial independence.

Key 2026 objectives include the H2 read-out of the CUV105 vitiligo trial and the summer regulatory filing for NEURACTHEL® in Europe. With 190 North American Specialty Centers targeted and expanded RD&I in Singapore, the Group is scaling to meet global demand in larger markets.

Read the letter here: https://brnw.ch/21wZ6Rr

$https://brnw.ch/21wZ6Rs $CLVLY

14/01/2026

In March 2025, we unveiled CLINUVEL’s ambitions at the American Academy of Dermatology (AAD) Annual Meeting ( ) in Orlando.

Our team hosted more than one guest per minute in our Pavilion of Photomedicine over three days, guiding visitors through the Company’s history, clinical programs, and future endeavours.

We will be back with more exciting stories and updates at in Denver, Colorado.
More updates to come!

12/01/2026

CLINUVEL’s Investor Relations team are excited to attend the first major investor event of 2026: the JP Morgan Biotech Healthcare Conference.

Taking place in San Francisco, JPM is the largest healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Maintaining active engagement with the life sciences community remains a priority for the Company, and we look forward to participating alongside leaders from across the healthcare sector at this significant event.

Myles Clouston, Head of US Investor Relations, will provide updates on the conference as it proceeds.

09/01/2026

Peptides are short chains of amino acids, which are the building blocks that make up proteins. Peptides are smaller and less complex than large proteins, yet they play essential biological roles.

CLINUVEL’s pharmaceutical development to date has focused on a family of peptides called melanocortins, which all originate from a common precursor called proopiomelanocortin (POMC).
Known physiological activity influenced by melanocortins includes pigmentation, inflammation, energy homeostasis, appetite and sexual function.

Learn more about melanocortins here: https://www.clinuvel.com/pharmaceuticals/the-science/melanocortins/

08/01/2026

We are officially counting down the weeks until !
Following the success of our Pavilion of Photomedicine in 2025, we cannot wait to share what is in store this year’s American Academy of Dermatology meeting in .

From fresh insights to new innovations, we are building something special.

Mark your calendar and watch this space for updates—you won’t want to miss this.

23/12/2025

As the festivities approach, CLINUVEL extends its warmest wishes to all who contribute to our mission - including patients, partners, researchers, physicians, ambassadors, advocates, shareholders, analysts, the wider community and our global team of CLINUVELLIANs.

Wishing everyone happy holidays and a prosperous new year.

09/12/2025

CLINUVEL today announced a significant expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This strategic five-year investment solidifies the site’s transition into a global hub for developing advanced, long-acting peptide formulations.

More details are available at: https://clinuvel.com/2025/12/clinuvel-expands-singapore-rdi-centre-to-pioneer-next-generation-peptide-therapies-20251208/

28/11/2025

Have you joined CLINUVEL’s Vitiligo Hub?

It aims to unite the vitiligo community and provide resources for those living with or caring for someone with this autoimmune condition.

Sign up here: https://brnw.ch/21wXTGw

25/11/2025

As a biotech company, CLINUVEL’s story is an unconventional one. Our Founder, Dr Philippe Wolgen, joined the Company’s Board in 2005, and has a few takeaways to share after 20 years of running the Company.

In this WIRED piece, Dr Wolgen discusses his philosophy and approach to having a focused strategy, recruiting talent, and navigating the challenging landscape of the industry.

Read the interview here: https://brnw.ch/21wXNGC

24/11/2025

As winter approaches in the Northern Hemisphere, sun protection remains important. Even though the weather is cooler and the sun feels weaker, ultraviolet (UV) radiation is still present.

UVA rays, which cause photodamage and skin cancer, are present all year and can even pass through clouds and windows.

UVB rays, responsible for sunburn and skin cancer, may be weaker in autumn, but they still contribute to long-term skin damage.
For those with conditions like , daily sun protection is essential since depigmented skin can burn more easily.

CLINUVEL recommends talking to your dermatologist about the best photoprotective regimen for your lifestyle and skin type, keeping in mind that the use of a broad-spectrum SPF sunscreen on exposed areas every day to protect against cumulative UV damage may be needed all year round.

21/11/2025

Erythropoietic protoporphyria (EPP) is characterised by intense phototoxic reactions when exposed to visible light sources. These debilitating reactions have been described as akin to “lava flowing underneath the skin” and have a significant impact upon quality of life for those living with EPP.

A recent study asked EPP patients about the experience of their most recent phototoxic reaction. Adults reported an average pain score of 7.6 out of 10, and adolescents reported a score of 7.2, with symptoms typically lasting about five days before resolving.

CLINUVEL is committed to advancing care for EPP patients worldwide, helping them receive the treatment they urgently need to reduce the impact of phototoxic reactions and improve daily life.

Address

535 Bourke Street
Melbourne, VIC
3000

Telephone

+61396604900

Website

https://www.clinuvel.com/

Alerts

Be the first to know and let us send you an email when CLINUVEL PHARMACEUTICALS LTD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CLINUVEL PHARMACEUTICALS LTD:

Want your practice to be the top-listed Clinic in Melbourne?